

Patient ID SA00147556	Patient Name TESTING, 288PD	Birth Date 1977-02-01	Gender F	Age 44
Order Number SA00147556	Client Order Number SA00147556	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 01 Sep 2021 08:00		

PD-L1 (28-8), SemiQuant IHC, Manual

Case Number CR-21-626

Interpretation

MCR

Testing, specimen for PD-L1 immunohistochemistry studies (clone 28-8, Abcam, Cambridge, MA; using a propriety detection system) (FR-21-99-A1):

0% tumor cells are positive PD-L1 (membranous positivity).

Interpretation: Pre-clinical studies suggest that positive PD-L1 immunohistochemistry in tumor cells and/or tumor-associated immune cells may predict tumor response to therapy with immune checkpoint inhibitors. This result should not be used as the sole factor in determining treatment, as other factors (for example, tumor mutation burden, and microsatellite instability) have been also studied as predictive markers.

Fixation: This test has been validated for non-decalcified paraffin embedded tissue specimens fixed in 10% neutral buffered formalin. This assay has not been validated on tissues subjected to the decalcification process and/or use of alternative fixatives for bone/bone marrow specimens or cell blocks.

Material Received

MCR

Report electronically signed by

MCR

A. FR-21-99: Testing
1 block

Alison Smarzyk Carlson

Disclaimer

MCR

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Received: 01 Sep 2021 11:52

Reported: 01 Sep 2021 12:06

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292